iBio reports fiscal Q1 2027 results, advances IBIO-600 and IBIO-610 programs
iBio completed single ascending dose testing for IBIO-600 and presented new preclinical data on IBIO-610 ahead of planned 2027 human trials.
SEC filing (2)
3 stories
iBio completed single ascending dose testing for IBIO-600 and presented new preclinical data on IBIO-610 ahead of planned 2027 human trials.
SEC filing (2)
The agreement, tied to Nuclea Canada's purchase of Moltex Energy's assets, is linked to a pending SPAC merger involving an affiliated sponsor entity.
SEC filing
The companies amended their license agreement to launch a three-phase Expansion Program advancing four AI-discovered compounds toward lead nomination in cardiac disease and obesity.
SEC filing (2)